Preliminary research suggests that levomefolic acid (L-methylfolate) taken with a [[First line agent|first-line]] [[antidepressant]]<ref>{{Cite journal|last=Sussman|first=Norman|date=March 1, 2009|title=Selecting a First-line Antidepressant: New Analysis|url=http://primarypsychiatry.com/selecting-a-first-line-antidepressant-new-analysis/|journal=Primary Psychiatry|volume=16|pages=19–22|pmid=}}</ref> may provide an [[Adjunctive therapy|adjunctive]] antidepressant effect for individuals who do not respond or have only a partial therapeutic response to [[Selective serotonin reuptake inhibitor|SSRI]] or [[Serotonin–norepinephrine reuptake inhibitor|SNRI]] medication.<ref>{{Cite journal|last=Ginsberg|first=Lawrence|last2=Oubre|first2=Alondra|last3=Daoud|first3=Yahya|date=January 2011|title=L-methylfolate Plus SSRI or SNRI from Treatment Initiation Compared to SSRI or SNRI Monotherapy in a Major Depressive Episode|journal=Innovations in Clinical Neuroscience|volume=8|issue=1|pages=19–28|pmc=3036555|pmid=21311704}}</ref><ref>{{Cite journal|last=Papakostas|first=George I.|last2=Shelton|first2=Richard C.|last3=Zajecka|first3=John M.|last4=Etemad|first4=Bijan|last5=Rickels|first5=Karl|last6=Clain|first6=Alisabet|last7=Baer|first7=Lee|last8=Dalton|first8=Elizabeth D.|last9=Sacco|first9=Garret R.|date=2012-12-01|title=L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials|journal=The American Journal of Psychiatry|volume=169|issue=12|pages=1267–1274|doi=10.1176/appi.ajp.2012.11071114|issn=1535-7228|pmid=23212058}}</ref><ref>{{Cite journal|last=Shelton|first=Richard C.|last2=Sloan Manning|first2=J.|last3=Barrentine|first3=Lori W.|last4=Tipa|first4=Eleanor V.|date=2013|title=Assessing Effects of l-Methylfolate in Depression Management: Results of a Real-World Patient Experience Trial|journal=The Primary Care Companion for CNS Disorders|volume=15|issue=4|doi=10.4088/PCC.13m01520|issn=2155-7772|pmc=3869616|pmid=24392264}}</ref><ref>{{Cite journal|last=Papakostas|first=George I.|last2=Shelton|first2=Richard C.|last3=Zajecka|first3=John M.|last4=Bottiglieri|first4=Teodoro|last5=Roffman|first5=Joshua|last6=Cassiello|first6=Clair|last7=Stahl|first7=Stephen M.|last8=Fava|first8=Maurizio|date=2014-04-15|title=Effect of Adjunctivel-Methylfolate 15 mg Among Inadequate Responders to SSRIs in Depressed Patients Who Were Stratified by Biomarker Levels and Genotype|url=http://www.psychiatrist.com/JCP/article/Pages/2014/v75n08/v75n0813.aspx|journal=The Journal of Clinical Psychiatry|language=English|volume=75|issue=08|pages=855–863|doi=10.4088/jcp.13m08947|issn=0160-6689}}</ref><ref>{{Cite journal|last=Shelton|first=Richard C.|last2=Pencina|first2=Michael J.|last3=Barrentine|first3=Lori W.|last4=Ruiz|first4=Juan A.|last5=Fava|first5=Maurizio|last6=Zajecka|first6=John M.|last7=Papakostas|first7=George I.|date=2015-12-23|title=Association of Obesity and Inflammatory Marker Levels on Treatment Outcome|url=http://www.psychiatrist.com/jcp/article/pages/2015/v76n12/v76n1212.aspx|journal=The Journal of Clinical Psychiatry|language=English|volume=76|issue=12|pages=1635–1641|doi=10.4088/jcp.14m09587|issn=0160-6689}}</ref><ref>{{Cite journal|last=Zajecka|first=John M.|last2=Fava|first2=Maurizio|last3=Shelton|first3=Richard C.|last4=Barrentine|first4=Lori W.|last5=Young|first5=Page|last6=Papakostas|first6=George I.|date=2016-05-25|title=Long-Term Efficacy, Safety, and Tolerability of <span style="font-variant:small-caps; "> l</span>-Methylfolate Calcium 15 mg as Adjunctive Therapy With Selective Serotonin Reuptake Inhibitors|url=http://www.psychiatrist.com/jcp/article/pages/2016/v77n05/v77n0521.aspx|journal=The Journal of Clinical Psychiatry|language=English|volume=77|issue=5|pages=654–660|doi=10.4088/jcp.15m10181|issn=0160-6689}}</ref>
